Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170126 · ClinicalTrials.gov registry record
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
A clinical trial of Multiple Sclerosis, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 1,182
- Enrollment target
- 3
- Study locations
NCT05170126: Recruiting study of Multiple Sclerosis, sponsored by Bristol-Myers Squibb.
NCT05170126 is a study of Multiple Sclerosis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,182 participants, above the 581-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (103% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05170126, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 1,182 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Conditions Studied
Study Locations (3)
Maryland
- Evidera INC. - Bethesda
- Evidera - Bethesda
Other
- Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum - Herne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,182 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2032-06-30 |
What NCT05170126 shows while recruiting
NCT05170126 is an observational study that tracks outcomes without assigning an intervention. Its 1,182 participants enrollment target places it among the larger protocols in the corpus, above the 581-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (103% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT05170126 reports a single indexed study location in Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT05170126 about?
NCT05170126 is a clinical study titled "A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring". The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
What is the current status of trial NCT05170126?
This trial is currently recruiting. The enrollment target is 1,182 participants. The study started on 2022-07-15. Estimated completion is 2032-06-30.
What conditions does trial NCT05170126 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
Who is sponsoring clinical trial NCT05170126?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05170126 being conducted?
This trial has 3 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05170126's enrollment target sits among peer trials
1,182 20th of 315 higher than 296 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT06931275 · 1,178 participants · NA
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI